Skip to main content
Genomic Vision logo

Genomic Vision — Investor Relations & Filings

Ticker · GV ISIN · FR0011799907 LEI · 969500UXJNBY1C8Y8471 PA Professional, scientific and technical activities
Open in API
Filings indexed 412 across all filing types
Latest filing 2023-06-23 Share Issue/Capital Cha…
Country FR France
Listing PA GV

About Genomic Vision

https://www.genomicvision.com/

Genomic Vision is a biotechnology company specializing in the direct visualization and analysis of single DNA molecules through its proprietary Molecular Combing technology. This platform provides highly accurate characterization of large-scale genomic modifications, offering critical insights into genetic integrity and stability. The company's primary focus is on providing quality control (QC) solutions for the bioproduction and cell and gene therapy markets, ensuring the safety and efficacy of advanced therapeutic products. In drug discovery, its Replication Combing Assay (RCA) is used to assess the effects of compounds on DNA replication. Genomic Vision's tools and services support the entire lifecycle of biopharmaceutical development, from research to production.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Share Issue/Capital Change Classification · 99% confidence The document is a press release from Genomic Vision announcing the drawdown of the 3rd tranche of a financing program structured as OCABSA (Obligations Convertibles avec Bons de Souscription d'Actions - Convertible Bonds with Warrants) from the investor Winance. This action relates directly to the company's fundraising and capital structure changes. This fits the definition of 'Capital/Financing Update' (CAP). Although it mentions future financial results (ER/IR), the primary focus and announcement are about the capital raise execution. It is not a full 10-K, AR, or a simple announcement of a report (RPA/RNS), but a specific corporate action regarding financing.
2023-06-23 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 100% confidence The document is a press release announcing a strategic business development: an exclusive distribution agreement between Genomic Vision and CliniSciences for European markets. This type of announcement, detailing a partnership, strategic shift, or commercial agreement, does not fit neatly into the specific financial reporting categories (like 10-K, IR, ER, or DIV). It is a general corporate announcement regarding business operations and strategy. Since it is not a formal regulatory filing like a 10-K or a specific report like an Audit Report (AR) or Earnings Release (ER), and it is not a proxy statement (DEF 14A) or a capital change (CAP/SHA), the most appropriate fallback category is 'Regulatory Filings' (RNS), which serves as a general category for significant, non-standard corporate news releases that are often filed with regulators.
2023-06-22 French
Inside Information / Other news releases
Regulatory Filings Classification · 100% confidence The document is a press release announcing an exclusive European distribution agreement between Genomic Vision and CliniSciences. It details strategic alignment, quotes CEOs, and includes standard company/contact information and a forward-looking statement. This type of announcement, which details a significant business development (like a partnership or agreement) but is not a formal regulatory filing like a 10-K, IR, or ER, typically falls under general corporate news. Since there is no specific category for 'Partnership Announcement' and it is not a financial report, management change, or capital event, the most appropriate general category is 'Regulatory Filings' (RNS) as a catch-all for significant, non-standard corporate disclosures, although 'LTR' (Legal Proceedings Report) or 'CAP' (Capital/Financing Update) are clearly incorrect. Given the context of a press release announcing a strategic business move, RNS is the best fit among the provided options for a general corporate announcement that isn't a core financial report or specific event filing.
2023-06-22 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release announcing a technology agreement between Genomic Vision and The Institute of Cancer Research (ICR) regarding the sale and use of FiberVision®S and FiberSmart® products. It details the terms of the agreement, the technology involved, and includes standard company boilerplate information and risk warnings. This type of announcement, which details a significant business development (a new contract/partnership) but is not a formal regulatory filing like a 10-K, an earnings release (ER), or a capital change (CAP), fits best under the general category for corporate news announcements that don't have a more specific code. Since it is a significant corporate event announcement, and not a report itself, it is classified as a Regulatory Filing (RNS) as the most appropriate general announcement category, as it is not a specific financial report, management change, or dividend notice. The length (over 10,000 characters) confirms it is the primary document, not just a brief announcement of a report (which would be RPA).
2023-06-20 French
Inside Information / Other news releases
Earnings Release Classification · 99% confidence The document is a press release announcing a specific business event: a technology agreement between Genomic Vision and The Institute of Cancer Research (ICR). It details the nature of the agreement (purchase of FiberVision®S and FiberSmart® products, upfront payment, and recurring revenue from consumables) and includes standard sections like 'ABOUT GENOMIC VISION', 'ABOUT ICR', and 'CONTACTS', concluding with a 'FORWARD LOOKING STATEMENT'. This type of announcement, detailing a strategic partnership, technology licensing, or significant commercial contract, does not fit neatly into the defined financial reporting categories (10-K, IR, ER, etc.). It is a general corporate announcement regarding business operations and strategy. Since it is not a report itself, nor a management change, dividend notice, or financing event, the most appropriate fallback category for a significant, non-standard corporate update is 'Regulatory Filings' (RNS), as it is a material announcement to the market. FY 2023
2023-06-20 English
Informations privilégiées / Autres communiqués
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document explicitly states it is a 'Déclaration au titre de l'article 223-16 du règlement général de l'Autorité des marchés financiers' (Declaration under Article 223-16 of the General Regulation of the AMF). This article typically relates to the total number of shares and voting rights, which is a mandatory regulatory disclosure in France. This type of filing, detailing the total number of shares and voting rights, is a specific regulatory announcement. It is not a full Annual Report (10-K), an Earnings Release (ER), or a Dividend Notice (DIV). It most closely aligns with a specific regulatory disclosure that doesn't fit the other precise categories. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for specific, non-standard regulatory disclosures, although it is a very specific type of regulatory filing. However, since the content is purely about the total number of shares and voting rights, and there is no specific code for 'Total Voting Rights Disclosure', RNS serves as the best fit among the provided codes for a mandatory regulatory filing that isn't a standard financial report or insider trade.
2023-06-16 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.